Ultragenyx Settles Dojolvi Patent Litigation With Navinta
Bitget2026/10/19 13:08- Ultragenyx Pharmaceutical and Baylor Research Institute settled DOJOLVI patent litigation with Navinta on October 19, 2026.
- Navinta will receive a non-exclusive, royalty-free license to market generic DOJOLVI beginning January 1, 2033, subject to customary conditions and exceptions.
- The launch date would move to July 1, 2033, if DOJOLVI receives pediatric exclusivity.
- The litigation stemmed from Navinta's application for FDA approval of a generic version of DOJOLVI oral liquid.
- Similar DOJOLVI patent litigation against other generic applicants remains pending in the U.S. District Court for the District of New Jersey.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cryptocurrencies Turn Higher as Equities Change Course -- Market Talk
U.S. homebuilder confidence unexpectedly falls to a 14-year low, hit by both high interest rates and cost pressures
The Housing Market Index, jointly released by the National Association of Home Builders (NAHB) and Wells Fargo, fell by 3 points this month to 29, the lowest level since June 2012 and below the market expectation of 31. The sales sub-index dropped to 33, also a 14-year low; the index for expected sales over the next six months declined to its weakest level since November 2022; the index measuring potential buyer traffic fell to its lowest point since the onset of the COVID-19 pandemic.
Crypto prices
More
